Structure-based  ||| S:0 E:16 ||| JJ
design  ||| S:16 E:23 ||| NN
of  ||| S:23 E:26 ||| IN
phthalimide  ||| S:26 E:38 ||| JJ
derivatives  ||| S:38 E:50 ||| NNS
as  ||| S:50 E:53 ||| IN
potential  ||| S:53 E:63 ||| JJ
cyclooxygenase-2  ||| S:63 E:80 ||| NNP
( ||| S:80 E:81 ||| -LRB-
COX-2 ||| S:81 E:86 ||| NNP
)  ||| S:86 E:88 ||| -RRB-
inhibitors ||| S:88 E:98 ||| NN
:  ||| S:98 E:100 ||| :
anti-inflammatory  ||| S:100 E:118 ||| JJ
and  ||| S:118 E:122 ||| CC
analgesic  ||| S:122 E:132 ||| JJ
activities  ||| S:132 E:143 ||| NNS
A  ||| S:143 E:145 ||| DT
group  ||| S:145 E:151 ||| NN
of  ||| S:151 E:154 ||| IN
30  ||| S:154 E:157 ||| CD
cyclic  ||| S:157 E:164 ||| CD
imides  ||| S:164 E:171 ||| NNS
( ||| S:171 E:172 ||| -LRB-
1-10a-c ||| S:172 E:179 ||| NNP
)  ||| S:179 E:181 ||| -RRB-
was  ||| S:181 E:185 ||| VBD
designed  ||| S:185 E:194 ||| VBN
for  ||| S:194 E:198 ||| IN
evaluation  ||| S:198 E:209 ||| NN
as  ||| S:209 E:212 ||| IN
a  ||| S:212 E:214 ||| DT
selective  ||| S:214 E:224 ||| JJ
COX-2  ||| S:224 E:230 ||| CD
inhibitor  ||| S:230 E:240 ||| NNS
and  ||| S:240 E:244 ||| CC
investigated  ||| S:244 E:257 ||| VBD
in vivo  ||| S:257 E:265 ||| CD
for  ||| S:265 E:269 ||| IN
anti-inflammatory  ||| S:269 E:287 ||| JJ
and  ||| S:287 E:291 ||| CC
analgesic  ||| S:291 E:301 ||| JJ
activities ||| S:301 E:311 ||| NNS
.  ||| S:311 E:313 ||| .
Compounds  ||| S:313 E:323 ||| NNP
6a ||| S:323 E:325 ||| NNP
,  ||| S:325 E:327 ||| ,
6b ||| S:327 E:329 ||| NNP
,  ||| S:329 E:331 ||| ,
7a  ||| S:331 E:334 ||| NNP
and  ||| S:334 E:338 ||| CC
7b  ||| S:338 E:341 ||| FW
exhibit  ||| S:341 E:349 ||| FW
optimal  ||| S:349 E:357 ||| FW
COX-2  ||| S:357 E:363 ||| FW
inhibitory  ||| S:363 E:374 ||| FW
potency  ||| S:374 E:382 ||| FW
( ||| S:382 E:383 ||| -LRB-
IC50 = 0.18 ||| S:383 E:394 ||| NNP
,  ||| S:394 E:396 ||| ,
0.24 ||| S:396 E:400 ||| CD
,  ||| S:400 E:402 ||| ,
0.28  ||| S:402 E:407 ||| CD
and  ||| S:407 E:411 ||| CC
0.36 μM ||| S:411 E:418 ||| NNP
;  ||| S:418 E:420 ||| :
respectively ||| S:420 E:432 ||| RB
)  ||| S:432 E:434 ||| -RRB-
and  ||| S:434 E:438 ||| CC
selectivity  ||| S:438 E:450 ||| JJ
index  ||| S:450 E:456 ||| NN
( ||| S:456 E:457 ||| -LRB-
SI ||| S:457 E:459 ||| NNP
)  ||| S:459 E:461 ||| -RRB-
range  ||| S:461 E:467 ||| NN
of  ||| S:467 E:470 ||| IN
363-668 ||| S:470 E:477 ||| CD
.  ||| S:477 E:479 ||| .
In vitro  ||| S:479 E:488 ||| NNP
COX-1 ||| S:488 E:493 ||| NNP
/ ||| S:493 E:494 ||| NNP
COX-2  ||| S:494 E:500 ||| NNP
inhibition  ||| S:500 E:511 ||| VBD
structure-activity  ||| S:511 E:530 ||| JJ
studies  ||| S:530 E:538 ||| NNS
identified  ||| S:538 E:549 ||| VBN
compound  ||| S:549 E:558 ||| JJ
6a  ||| S:558 E:561 ||| NN
as  ||| S:561 E:564 ||| IN
a  ||| S:564 E:566 ||| DT
highly  ||| S:566 E:573 ||| RB
potent  ||| S:573 E:580 ||| JJ
( ||| S:580 E:581 ||| -LRB-
IC50 = 0.18 μM ||| S:581 E:595 ||| NNP
) ||| S:595 E:596 ||| -RRB-
,  ||| S:596 E:598 ||| ,
and  ||| S:598 E:602 ||| CC
an  ||| S:602 E:605 ||| DT
extremely  ||| S:605 E:615 ||| RB
selective  ||| S:615 E:625 ||| JJ
[ ||| S:625 E:626 ||| -LRB-
COX-2  ||| S:626 E:632 ||| NNP
( ||| S:632 E:633 ||| -LRB-
SI ||| S:633 E:635 ||| NNP
) ||| S:635 E:636 ||| -RRB-
 = 668 ||| S:636 E:642 ||| CD
]  ||| S:642 E:644 ||| -RRB-
comparable  ||| S:644 E:655 ||| JJ
to  ||| S:655 E:658 ||| TO
celecoxib  ||| S:658 E:668 ||| VB
[ ||| S:668 E:669 ||| -LRB-
COX-2  ||| S:669 E:675 ||| NNP
( ||| S:675 E:676 ||| -LRB-
SI ||| S:676 E:678 ||| NNP
) ||| S:678 E:679 ||| -RRB-
  ||| S:679 E:680 ||| CD
> ||| S:680 E:681 ||| CD
 384 ||| S:681 E:685 ||| CD
] ||| S:685 E:686 ||| -RRB-
,  ||| S:686 E:688 ||| ,
COX-2  ||| S:688 E:694 ||| CD
inhibitor  ||| S:694 E:704 ||| NNS
that  ||| S:704 E:709 ||| WDT
showed  ||| S:709 E:716 ||| VBD
superior  ||| S:716 E:725 ||| JJ
anti-inflammatory  ||| S:725 E:743 ||| JJ
activity  ||| S:743 E:752 ||| NN
( ||| S:752 E:753 ||| -LRB-
ED50 = 54.0 mg ||| S:753 E:767 ||| FW
/ ||| S:767 E:768 ||| FW
kg ||| S:768 E:770 ||| FW
)  ||| S:770 E:772 ||| -RRB-
relative  ||| S:772 E:781 ||| JJ
to  ||| S:781 E:784 ||| TO
diclofenac  ||| S:784 E:795 ||| VB
( ||| S:795 E:796 ||| -LRB-
ED50 = 114 mg ||| S:796 E:809 ||| FW
/ ||| S:809 E:810 ||| FW
kg ||| S:810 E:812 ||| FW
) ||| S:812 E:813 ||| -RRB-
. Molecular  ||| S:813 E:825 ||| NNP
Docking  ||| S:825 E:833 ||| NNP
study  ||| S:833 E:839 ||| NN
of  ||| S:839 E:842 ||| IN
the  ||| S:842 E:846 ||| DT
synthesized  ||| S:846 E:858 ||| JJ
compound  ||| S:858 E:867 ||| NN
6a  ||| S:867 E:870 ||| NN
into  ||| S:870 E:875 ||| IN
the  ||| S:875 E:879 ||| DT
active  ||| S:879 E:886 ||| JJ
site  ||| S:886 E:891 ||| NN
of  ||| S:891 E:894 ||| IN
COX-2  ||| S:894 E:900 ||| NNP
revealed  ||| S:900 E:909 ||| VBD
a  ||| S:909 E:911 ||| DT
similar  ||| S:911 E:919 ||| JJ
binding  ||| S:919 E:927 ||| JJ
mode  ||| S:927 E:932 ||| NN
to  ||| S:932 E:935 ||| TO
SC-558 ||| S:935 E:941 ||| CD
,  ||| S:941 E:943 ||| ,
a  ||| S:943 E:945 ||| DT
selective  ||| S:945 E:955 ||| JJ
COX-2  ||| S:955 E:961 ||| CD
inhibitor ||| S:961 E:970 ||| NNS
.  ||| S:970 E:972 ||| .
Docking  ||| S:972 E:980 ||| JJ
study  ||| S:980 E:986 ||| NN
showed  ||| S:986 E:993 ||| VBD
that  ||| S:993 E:998 ||| IN
the  ||| S:998 E:1002 ||| DT
methoxy  ||| S:1002 E:1010 ||| JJ
moeities  ||| S:1010 E:1019 ||| NN
of  ||| S:1019 E:1022 ||| IN
6a  ||| S:1022 E:1025 ||| NNP
inserted  ||| S:1025 E:1034 ||| VBD
deep  ||| S:1034 E:1039 ||| RB
inside  ||| S:1039 E:1046 ||| IN
the  ||| S:1046 E:1050 ||| DT
2°-pocket  ||| S:1050 E:1060 ||| NN
of  ||| S:1060 E:1063 ||| IN
the  ||| S:1063 E:1067 ||| DT
COX-2  ||| S:1067 E:1073 ||| JJ
active  ||| S:1073 E:1080 ||| JJ
site ||| S:1080 E:1084 ||| NN
,  ||| S:1084 E:1086 ||| ,
where  ||| S:1086 E:1092 ||| WRB
the  ||| S:1092 E:1096 ||| DT
O-atoms  ||| S:1096 E:1104 ||| JJ
of  ||| S:1104 E:1107 ||| IN
such  ||| S:1107 E:1112 ||| JJ
groups  ||| S:1112 E:1119 ||| NNS
underwent  ||| S:1119 E:1129 ||| VBD
an  ||| S:1129 E:1132 ||| DT
H-bonding  ||| S:1132 E:1142 ||| JJ
interaction  ||| S:1142 E:1154 ||| NN
with  ||| S:1154 E:1159 ||| IN
His ||| S:1159 E:1162 ||| PRP$
( ||| S:1162 E:1163 ||| -LRB-
90 ||| S:1163 E:1165 ||| CD
)  ||| S:1165 E:1167 ||| -RRB-
( ||| S:1167 E:1168 ||| -LRB-
3.02 Å ||| S:1168 E:1174 ||| NNP
) ||| S:1174 E:1175 ||| -RRB-
,  ||| S:1175 E:1177 ||| ,
Arg ||| S:1177 E:1180 ||| NNP
( ||| S:1180 E:1181 ||| -LRB-
513 ||| S:1181 E:1184 ||| LS
)  ||| S:1184 E:1186 ||| -RRB-
( ||| S:1186 E:1187 ||| -LRB-
1.94 ||| S:1187 E:1191 ||| CD
,  ||| S:1191 E:1193 ||| ,
2.83 Å ||| S:1193 E:1199 ||| CD
) ||| S:1199 E:1200 ||| -RRB-
,  ||| S:1200 E:1202 ||| ,
and  ||| S:1202 E:1206 ||| CC
Gln ||| S:1206 E:1209 ||| NNP
( ||| S:1209 E:1210 ||| -LRB-
192 ||| S:1210 E:1213 ||| LS
)  ||| S:1213 E:1215 ||| -RRB-
( ||| S:1215 E:1216 ||| -LRB-
3.25 Å ||| S:1216 E:1222 ||| NNP
) ||| S:1222 E:1223 ||| -RRB-
.  ||| S:1223 E:1225 ||| .
